MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Sloan Ratio % : 14.48% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

MoonLake Immunotherapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 was 14.48%.

As of Mar. 2024, MoonLake Immunotherapeutics has a Sloan Ratio of 14.48%, indicating there is a warning stage of accrual build up.

MoonLake Immunotherapeutics Sloan Ratio % Historical Data

The historical data trend for MoonLake Immunotherapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Sloan Ratio % Chart

MoonLake Immunotherapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Sloan Ratio %

49.79

6.07

MoonLake Immunotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial							-	-0.84	25.69	6.07	14.48

Competitive Comparison of MoonLake Immunotherapeutics's Sloan Ratio %

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Sloan Ratio % falls into.

MoonLake Immunotherapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

MoonLake Immunotherapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-36.007	-	-42.778
	-	-25.184)	/	526.54
	=	6.07%

MoonLake Immunotherapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Mar. 2024 )
	=	(-40.676	-	-48.702
	-	-73.637)	/	564.117
	=	14.48%

MoonLake Immunotherapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -10.139 (Jun. 2023 ) + -9.426 (Sep. 2023 ) + -7.437 (Dec. 2023 ) + -13.674 (Mar. 2024 ) = $-40.68 Mil.
MoonLake Immunotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -12.159 (Jun. 2023 ) + -9.251 (Sep. 2023 ) + -12.344 (Dec. 2023 ) + -14.948 (Mar. 2024 ) = $-48.70 Mil.
MoonLake Immunotherapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 12.676 (Jun. 2023 ) + -174.376 (Sep. 2023 ) + 116.867 (Dec. 2023 ) + -28.804 (Mar. 2024 ) = $-73.64 Mil.

MoonLake Immunotherapeutics (NAS:MLTX) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, MoonLake Immunotherapeutics has a Sloan Ratio of 14.48%, indicating there is a warning stage of accrual build up.

MoonLake Immunotherapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300